Literature DB >> 17559076

Regulation of GLUT3 and glucose uptake by the cAMP signalling pathway in the breast cancer cell line ZR-75.

Ana Maria Meneses1, Rodolfo A Medina, Sumie Kato, Mauricio Pinto, Maria Paz Jaque, Isabel Lizama, María de los Angeles García, Francisco Nualart, Gareth I Owen.   

Abstract

Increased glucose uptake as a principal energy source is a requirement for the continued survival of tumour cells. Facilitative glucose transporter-1 (GLUT1) and -3 (GLUT3) have been previously shown to be present and regulated in breast cancer cells and are associated with poor patient prognosis. In cancer cells, the cAMP secondary messenger pathway is known to potentiate described glucose transporter activators and regulate cell fate. However, no regulation of the glucose transporters in breast cancer cells by cAMP has previously been examined. Herein, we determined in the well-characterized breast cancer cell line ZR-75, if the cAMP analogue 8-br-cAMP was capable of regulating GLUT1 and GLUT3 expression and thus glucose uptake. We demonstrated that 8-br-cAMP transiently up-regulates GLUT3 mRNA levels. The use of actinomycin-D and the cloning of 1,200 bp upstream of the human GLUT3 promoter demonstrated that this regulation was transcriptional. Immunocytochemistry and Western blotting confirmed that the increase in mRNA was reflected by an increase in protein levels. No notable regulation of GLUT1 in the presence of 8-br-cAMP was detected. Finally, we determined using the non-metabolizable glucose analogue 2-DOG if this up-regulation in GLUT3 increased glucose uptake. We observed the presence of two uptake components, one corresponding to the Km of GLUT1/4 and the other to GLUT3. A doubling in the uptake velocity was observed only at the Km corresponding to GLUT3. In conclusion, we demonstrate and characterize for the first time, an up-regulation of GLUT3 mRNA, protein and glucose uptake by the cAMP pathway in breast cancer cells. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17559076     DOI: 10.1002/jcp.21166

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis.

Authors:  M A Kocdor; H Kocdor; J S Pereira; J E Vanegas; I H Russo; J Russo
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

2.  Research resource: expression profiling reveals unexpected targets and functions of the human steroid receptor RNA activator (SRA) gene.

Authors:  Charles E Foulds; Anna Tsimelzon; Weiwen Long; Andrew Le; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Mol Endocrinol       Date:  2010-03-10

Review 3.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

4.  CREB1 regulates glucose transport of glioma cell line U87 by targeting GLUT1.

Authors:  Jiaying Chen; Can Zhang; Yang Mi; Fuxue Chen; Dongshu Du
Journal:  Mol Cell Biochem       Date:  2017-06-23       Impact factor: 3.396

5.  Asymmetric distribution of glucose transporter mRNA provides a growth advantage in yeast.

Authors:  Timo Stahl; Stefan Hümmer; Nikolaus Ehrenfeuchter; Nitish Mittal; Geoffrey Fucile; Anne Spang
Journal:  EMBO J       Date:  2019-03-25       Impact factor: 11.598

Review 6.  Nutrient transporters: the Achilles' heel of anabolism.

Authors:  Alison N McCracken; Aimee L Edinger
Journal:  Trends Endocrinol Metab       Date:  2013-02-08       Impact factor: 12.015

Review 7.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

8.  Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM.

Authors:  Dong-Wei Dai; Qiong Lu; Lai-Xing Wang; Wen-Yuan Zhao; Yi-Qun Cao; Ya-Nan Li; Guo-Sheng Han; Jian-Min Liu; Zhi-Jian Yue
Journal:  BMC Cancer       Date:  2013-10-14       Impact factor: 4.430

9.  Osteopontin upregulates the expression of glucose transporters in osteosarcoma cells.

Authors:  I-Shan Hsieh; Rong-Sen Yang; Wen-Mei Fu
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

10.  Ajuba Overexpression Promotes Breast Cancer Chemoresistance and Glucose Uptake through TAZ-GLUT3/Survivin Pathway.

Authors:  Xiang Li; Gexin Zhao; Xiaoyi Mi; Tonghong Xu; Xinmin Li; Bin Liu
Journal:  Biomed Res Int       Date:  2022-02-07       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.